Figure 6.
EGF treatment effects on HSC mutagenesis and gene expression following TBI. Representative Circos plots of WGS of BM KSL cells collected from C57BL/6 mice at 6 weeks following 500-cGy TBI and treatment with saline (A) or EGF (B). (C) Total genome variant numbers categorized by mutation type (n = 5 per group, mean ± SEM, 2-way ANOVA). (D) Numbers and locations of CNVs in BM KSL cells at 6 weeks following 500-cGy TBI and treatment with EGF or saline (n = 5 per group, mean ± SEM). ****P < .0001, 2-way ANOVA. (E) Numbers and locations of SNPs in BM KSL cells at 6 weeks following 500-cGy TBI and treatment with EGF or saline (n = 5 per group, mean ± SEM, 2-way ANOVA). (F) Numbers and locations of InDels in BM KSL cells at 6 weeks following 500-cGy TBI and treatment with EGF or saline (n = 5 per group, mean ± SEM, 2-way ANOVA). UTR, untranslated region.

EGF treatment effects on HSC mutagenesis and gene expression following TBI. Representative Circos plots of WGS of BM KSL cells collected from C57BL/6 mice at 6 weeks following 500-cGy TBI and treatment with saline (A) or EGF (B). (C) Total genome variant numbers categorized by mutation type (n = 5 per group, mean ± SEM, 2-way ANOVA). (D) Numbers and locations of CNVs in BM KSL cells at 6 weeks following 500-cGy TBI and treatment with EGF or saline (n = 5 per group, mean ± SEM). ****P < .0001, 2-way ANOVA. (E) Numbers and locations of SNPs in BM KSL cells at 6 weeks following 500-cGy TBI and treatment with EGF or saline (n = 5 per group, mean ± SEM, 2-way ANOVA). (F) Numbers and locations of InDels in BM KSL cells at 6 weeks following 500-cGy TBI and treatment with EGF or saline (n = 5 per group, mean ± SEM, 2-way ANOVA). UTR, untranslated region.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal